Significance of chromosomal alterations and mutations of the N-RAS and TP53 genes in relation to leukemogenesis of acute myeloid leukemia

Leukemia Research

Volumn 22, Issue 7, 1998, Pages 631-637

  Misawa, Shinichi ^a,b   Horiike, Shigeo ^b   Kaneko, Hiroto ^b   Sasai, Yuri ^b   Ueda, Yutaka ^b   Nakao, Makoto ^b   Yokota, Shouhei ^b   Taniwaki, Masafumi ^b   Fujii, Hiroshi ^c   Nakagawa, Hitoshi ^c   Tsuda, Shouichirou ^d   Kashima, Kei ^b  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^c KYOTO FIRST RED CROSS HOSPITAL   (Japan)

^d Aiseikai Yamashina Hospital   (Japan)

Author keywords

AML; Chromosomes; Multistep carcinogenesis; N RAS mutation; Secondary leukemia; TP53 mutation

Indexed keywords

ALKYLATING AGENT; PROTEIN P53;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CHROMOSOME ABERRATION; CHROMOSOME INVERSION; FEMALE; GENE MUTATION; HUMAN; HUMAN CELL; LEUKEMOGENESIS; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASIA; MYELODYSPLASTIC SYNDROME; ONCOGENE N RAS; PRIORITY JOURNAL; RECIPROCAL CHROMOSOME TRANSLOCATION; TUMOR SUPPRESSOR GENE;

ACUTE DISEASE; ADULT; AGED; AGED, 80 AND OVER; CHROMOSOME ABERRATIONS; CHROMOSOMES; CHROMOSOMES, HUMAN, PAIR 17; CHROMOSOMES, HUMAN, PAIR 5; CHROMOSOMES, HUMAN, PAIR 7; FEMALE; GENES, P53; GENES, RAS; HUMANS; KARYOTYPING; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; MUTATION;

EID: 0031842170     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(98)00056-3     Document Type: Article

References (31)

1. Fearon E.R., Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 61:1990;759.
2. Pedeersen-Bjergaard J., Pedersen M., Rouston D., Philip P. Different genetic pathways in leukemogenesis for patients presenting with therapy-related myelodysplasia and therapy-related acute myeloid leukemia. Blood. 96:1995;3542.
3. Misawa S., Yashige H., Horiike S., Taniwaki M., Nishigaki K., Okuda T., Yokota S., Tsuda S., Edagawa J., Imanishi H., Takino T., Inazawa J., Abe T., Nakanishi S., Nakagawa M., Kobayashi H., Maekawa T., Fujii H., Akaogi T., Hayashi H., Fujiyama Y., Kohsaki M. Detection of karyotypic abnormalities in most patients with acute nonlymphocytic leukemia by adding ethidium bromide to short-term cultures. Leukemia Res. 12:1988;719.
4. Rabbitts T.H. Chromosomal translocations in human cancer. Nature. 372:1994;143.
5. Kantarjian H.M., Estey E.H., Keating M.J. Treatment of therapy-related leukemia and myelodysplastic syndrome. Hematol Oncol Clin North Am. 7:1993;81.
6. Pedersen-Bjergaard J., Rowley J.D. The balanced and the unbalanced chromosome aberrations of acute myeloid leukemia may develop in different ways and may contribute differently to malignant transformation. Blood. 83:1994;2780.
7. Horrigan S.K., Westbrook C.A., Kim A.H., Banerjee M., Stock W., Larson R.A. Polymerase chain reaction-based diagnosis of del(5q) in acute myeloid leukemia and myelodysplastic syndrome identifies a minimal deletion interval. Blood. 88:1996;2665.
8. Le Beau M.M., Espinosa R. III, Davis E.M., Eisenbart J.D., Larson R.A., Green E.D. Cytogenetic and molecular delineation of a region of chromosome 7 commonly deleted in malignant myeloid diseases. Blood. 88:1996;1930.
9. Brito-Babapulle F., Catovsky D., Galton D.A.G. Clinical and laboratory features of de novo acute myeloid leukemia with trilineage myslodysplasia. Br J Haematol. 66:1987;445.
10. Bennett J.M., Catovsky D., Daniel M.T., Flandrin G., Galton D.A.G., Gralnik H.R., Sultan C. The French-American-British (FAB) Co-operative Group: Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 51:1982;189.
11. Stepehnson J., Mufti G.J., Yoshida Y. Myelodysplastic syndromes: from morphology to molecular biology. Part II. The molecular genetics of myelodysplasia. Int J Hematol. 57:1993;99.
12. Horiike S., Misawa S., Nakai H., Kaneko H., Taniwaki M., Yamane Y., Inazawa J., Abe T., Kashima K. N-ras mutation and karyotypic evolution are closely associated with leukemia transformation in myelodysplastic syndrome. Leukemia. 8:1994;1331.
13. Kaneko H., Misawa S., Horiike S., Nakai H., Kashima K. TP53 mutations emerge at early phase of myelodysplastic syndrome and are associated with complex chromosomal abnormalities. Blood. 85:1995;2189.
14. Dastugue N., Payen C., Lafage-Pochitaloff M., Bernard P., Leroux D., Huguet-Rigal F., Stoppa A.-M., Marit G., Molina L., Michallet M., Maraninchi D., Attal M., Reiffers J. Prognostic significance of karyotype in de novo adult acute myeloid leukemia. Leukemia. 9:1995;1419.
15. Bennett J.M., Catovsky D., Daniel M.T., Flandrin G., Galton D.A.G., Gralnik H.R., Sultan C. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British (FAB) Co-operative Group. Ann Int Med. 103:1985;626.
16. ISCN. In: Mitelman F, editor. An International System for Human Cytogentics. Karger, Basel, 1995.
17. Horiike S., Misawa S., Kaneko H., Nakai H., Ueda Y., Nakao M., Hirakawa K., Taniwaki M., Kashima K. Doubel mutations of the N-ras gene in a patient with acute myelomonocytic leukemia. Int J Hematol. 61:1995;205.
18. Yoneda-Kato N., Look A.T., Kirstein M.N., Valentine M.B., Raimondi S.C., Cohen K.J., Carroll A.J., Morris S.W. The t(3;5)(q25.1;q34) of myelodysplastic syndrome and acute myeloid leukemia produces a novel fusion gene, NPM-MLF1. Oncogene. 12:1996;265.
19. Raynaud S.D., Baens M., Grosgeorge J., Rodgers K., Reid C.D., Dainton M., Dyer M., Fuzibet J.G., Gratecos N., Taillan B., Ayraud N., Marynen P. Fluorescence in situ hybridization analysis of t(3;12)(q26;p13): a recurring chromosomal abnormality involving the TEL gene (ETV6) in myelodysplastic syndromes. Blood. 88:1996;682.
20. Borrow J., Shearman A.M., Stanton V.P. Jr., Becher R., Collins T., Williams A.J., Dube I., Katz F., Kwong Y.L., Morris C., Ohyashiki K., Toyama K., Rowley J., Housman D.E. The t(7;11)(p15;p15) translocation in acute myeloid leukemia fuses the genes for nucleoprotein NUP98 and class I homeoprotein HOXA9. Nature Genet. 12:1996;159.
21. Harris C.C., Hollstein M. Clinical implications of the p53 tumor-supressor gene. New Engl J Med. 329:1993;1318.
22. Gahn B., Haase D., Unterhalt M., Drescher M., Schoch C., Fonatsch C., Terstappen L.W.M.M., Hiddemann W., Buchner T., Bennett J.M., Wormann B. De novo AML with dysplastic hematopoiesis: cytogenetic and prognostic significcance. Leukemia. 10:1996;946.
23. Fenaux P., Jonveaux P., Quiquandron I., Lai J.L., Pignon J.M., Loucheux-Lefebvre M.H., Bauters F., Berger R., Kerckaert J.P. P53 gene mutations in acute myeloid leukemia with 17p monosomy. Blood. 78:1991;652.
24. Lane D.P. p53, guardian of the genome. Nature. 358:1992;15.
25. Radich J.P., Kopecky K.J., Appelbaum F., Willman C.L., Colloins S.J. N-ras mutyations in acute myelogenous leukemia: A review of the current literature and an update of the Southwest Oncology Group experience. Leukemia Lymphoma. 6:1992;325.
26. Hollstein M., Sidransky D., Vogelstein B., Harris C.C. p53 mutations in human cancers. Science. 253:1991;49.
27. de Fromentel C.C., Soussi T. TP53 tumor supressor gene: A model for investigating human mutagenesis. Genes Chromosomes Cancer. 4:1992;1.
28. Misawa S., Horiike S. TP53 mutation in myelodysplastic syndrome. Leukemia Lymphoma. 23:1996;417.
29. Barbacid M. ras oncogenes: their role in neoplasia. Eur J Clin Invest. 20:1990;225.
30. Bos J.L. ras oncogenes in human cancer: A review. Cancer Res. 49:1989;4682.
31. 1-negative chronic myelocytic leukemia. Hum Genet. 83:1989;115.